Chilean authorities gave approval to Elanco for its Imvixa drug that is given to Atlantic salmon and trout to fight caligus in fish, the company said.
Imvixa is administered to fish orally during their freshwater phase and has been shown to reduce chitin in caligus that stops them from becoming adults, the company said in a statement.
“The control of the parasite generates constant pressure for salmon producers, it is time consuming, complicated and stressful for the fish and as much for the aquaculture companies,” Carlos Kuada, Elanco’s global director for the aquaculture business. “Elanco is proud to take this treatment to production centers responding to a big need for the Chilean salmon industry.”
Caligus costs the salmon industry $1 billion in extra costs annually, and Chile also suffers from the presence of caligus rogercresseyi, a strand of the parasite.
Fish treated with Imvixa in lab tests were within the regulatory limits for parasites on fish, comparing favourably to untreated fish, the company said. Another company, Tecnovax, launched a sea lice vaccine in Chile last year.
Elanco has been operating since 1953 and has a presence in more than 70 countries, according to the company’s website. (undercurrent News)